Strategies to eliminate cancer stem cells: Clinical implications

Research output: Contribution to journalArticlepeer-review

Abstract

Over the past two decades, major advances in our understanding of cancer have translated into only modest increments in survival for the majority of cancer patients. Recent data suggesting cancers arise from rare self-renewing stem cells that are biologically distinct from their more numerous differentiated progeny may explain this paradox. Current anticancer therapies have been developed to decrease the bulk of the tumour mass (i.e. the differentiated cancer cells). Although treatments directed against the bulk of the cancer may produce dramatic responses, they are unlikely to result in long-term remissions if the rare cancer stem cells are also not targeted. Conversely, treatments that selectively attack cancer stem cells will not immediately eliminate the differentiated cancer cells, and might therefore be prematurely abandoned if clinical activity is judged solely by traditional response criteria that reflect changes in the bulk of the tumour. Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers.

Original languageEnglish (US)
Pages (from-to)1293-1297
Number of pages5
JournalEuropean Journal of Cancer
Volume42
Issue number9
DOIs
StatePublished - Jun 1 2006

Keywords

  • Cancer stem cells
  • Cell differentiation
  • Chronic myeloid leukaemia
  • Drug resistance
  • Imatinib
  • Stem cells
  • Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Strategies to eliminate cancer stem cells: Clinical implications'. Together they form a unique fingerprint.

Cite this